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Background: Despite considerable recent progress in the treatment of lung adenocarcinoma, there has been little
progress in the development of efficacious molecular targeted therapies for squamous cell lung cancer. In addition
to the recent comprehensive genome-wide characterization of squamous cell lung cancer, it is also important to
genotype this form of cancer. We therefore conducted the Shizuoka Lung Cancer Mutation Study to analyze driver
mutations in patients with thoracic malignancies. Here we report the results of genotyping in patients with squamous
cell lung cancer.
Methods: Based on the biobanking system, in conjunction with the clinic and pathology lab, we developed a
genotyping panel designed to assess 24 mutations in 10 genes (EGFR, KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, HER2
and DDR2), EGFR, MET, PIK3CA, FGFR1 and FGFR2 copy numbers, and EML4-ALK and ROS1 translocations, using
pyrosequencing plus capillary electrophoresis, quantitative polymerase chain reaction (PCR) and reverse-transcription
PCR, respectively.
Results: A total of 129 patients with squamous cell lung cancer and adenosquamous carcinoma were enrolled in this
study between July 2011 and November 2012. We detected genetic alterations in 40% of all cases. Gene alterations
included: EGFR mutations, 6%; KRAS mutations, 4%; PIK3CA mutations, 13%; NRAS mutations, 1%; KIF5b-RET fusion gene,
1%; EGFR copy number gain, 5%; PIK3CA copy number gain, 15%; and FGFR1 copy number gain, 5%. Twelve
patients (9%) harbored simultaneous genetic alterations. Genetic alterations were detected more frequently in
surgically-resected, snap-frozen samples than in formalin-fixed, paraffin-embedded samples (50% vs. 29%). In
addition, patients aged ≤70 years old and never-smokers showed high frequencies of genetic alterations.
Conclusions: This study represents one of the largest prospective tumor-genotyping studies to be performed in
Asian patients with squamous cell lung cancer. These results suggest that incorporation of genetic profiling into
lung cancer clinical practice may facilitate the administration of personalized cancer treatments in patients with
squamous cell lung cancer.
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Non-small-cell lung cancer (NSCLC) has recently been
divided into nonsquamous cell carcinoma and squamous
cell carcinoma. Pemetrexed and bevacizumab have been
approved for the treatment of nonsquamous cell lung
cancer [1,2]. In addition, epidermal growth factor recep-
tor (EGFR) mutations and anaplastic lymphoma kinase
(ALK) fusion genes have been identified in lung adeno-
carcinoma, and are considered as biomarkers for EGFR
and ALK inhibitors [3-7]. Treatment for nonsquamous
cell lung cancer has therefore advanced, including options
for personalized therapy.
Squamous cell lung cancer is a major histological sub-
type of NSCLC, accounting for 30% of NSCLC. How-
ever, in contrast to adenocarcinomas, little progress has
been achieved in the development of efficacious molecularTable 1 Multiple tumor genotyping panel
Gene Position AA mutant Nucleotide mutant
EGFR G719 G719C/S 2155G > T/A
G719A 2156G > C
exon 19 deletion
T790 T790M 2369C > T
exon 20 insertion
L858 L858R 2573 T > G
L861 L861Q 2582 T > A
KRAS G12 G12C/S/R 34G > T/A/C
G12V/A/D 35G > T/C/A
G13 G13C/S/R 37G > T/A/C
G13D/A 38G > A/C
Q61 Q61K 181C > A
Q61R/L 182A > G/T
Q61H 183A > T/C
BRAF G466 G466V 1397G > T
G469 G469A 1406G > C
L597 L597V 1789C > G
V600 V600E 1799 T > A
PIK3CA E542 E542K 1624G > A
E545 E545K/Q 1633G > A/C
H1047 H1047R 3140A > G
NRAS Q61 Q61K 181C > A
Q61L/R 182A > T/G
MEK1 (MAP2K1) Q56 Q56P 167A > C
K57 K57N 171G > T
D67 D67N 199G > A
AKT1 E17 E17K 49G > A
PTEN R233 R233* 697C > T
HER2 exon 20 insertion
DDR2 S768 S768R 2304 T > Atargeted therapies for squamous cell lung cancer. Compre-
hensive genome-wide characterization of squamous cell
lung cancer has recently revealed some potential drug
targets [8-10]. However, differences in frequencies of some
genetic alterations, including EGFR and KRAS mutations,
have been identified between Asian and Western patients
[11], and it is therefore important to assess the frequencies
of genetic alterations in squamous cell lung cancer in
different ethnic groups, including in Asian patients.
We developed a tumor-genotyping panel to screen lung
cancer patients for genetic alterations relevant to novel
molecular-targeted therapeutics in ongoing clinical trials
[12-15] (Additional file 1: Table S1). Genotyping analysis
was implemented in the Shizuoka Lung Cancer Mutation
Study, which is a prospective tumor-genotyping study
conducted in patients admitted to Shizuoka Cancer Center
with thoracic malignancies. This paper reports the results
of this study in relation to genetic alterations in squamous
cell lung cancer and adenosquamous carcinoma.
Methods
Patients and samples
The Shizuoka Lung Cancer Mutation Study was initiated
in July 2011 to analyze driver mutations in patients with
thoracic malignancies. The study subjects were patientsTable 2 Patient characteristics (overall, n =129)
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http://www.biomedcentral.com/1471-2407/14/786with pathologically-diagnosed thoracic malignancies, who
had provided written informed consent. The diagnosis
and differentiation of squamous cell carcinoma and ade-
nosquamous carcinoma were confirmed by institutional
pathologists, in accordance with the 2004 World Health
Organization classification. When samples were difficult
to diagnose as squamous cell carcinoma, immunohisto-
chemical analyses were performed (i.e., thyroid tran-
scription factor 1, p63 staining). Surgically-resected tissue
specimens were macrodissected by the same pathologists
to enrich the tumor content. Tumor biopsy specimens con-
taining ≥10% tumor content, as evaluated by hematoxylin-
eosin staining, were used for this study. All specimens
from 129 patients with squamous cell lung cancer were
thus considered adequate for genotyping. Surgically-resected
tissues were snap-frozen on dry ice immediately afterA
B
Figure 1 Relative proportions of genetic alterations in squamous cel
A: Pie chart shows relative proportions of genetic alterations. B: Bar chart s
copy number gain.resection and stored at −80°C until use. Formalin-fixed,
paraffin-embedded (FFPE) specimens, mainly including
biopsy samples, were sectioned at a thickness of 10 μm.
All the relevant clinicopathological information, including
smoking history, was retrieved from the patients’ medical
records. We defined “light smokers” as those who smoked
<30 packs per year, and “heavy smokers” as those who
smoked ≥30 packs per year.
Genetic profiling
We developed a tumor genotyping panel (Table 1) to assess
24 hot-spot sites of genetic alterations in 10 genes (EGFR,
KRAS, BRAF, PIK3CA, NRAS, MEK1, AKT1, PTEN, HER2
and DDR2), EGFR, MET, PIK3CA, FGFR1 and FGFR2
copy number gains, and EML4-ALK, KIF5B-RET, CCDC6-
RET, CD74-ROS1 and SLC34A2-ROS1 fusion genes usingl lung cancer and adenosquamous carcinoma (overall, n = 129).
hows relative proportions of genetic alterations. MUT: mutant, CNG:
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tative polymerase chain reaction (PCR), and reverse-
transcription PCR, respectively. These genetic alterations
were selected based on the articles listed in Additional
file 1: Table S1. Detailed methods are described in
Additional file 2 [16]. Fusion genes were accessed only
with fresh-frozen tissues.
Statistical analysis
All categorical variables were analyzed by χ2 or Fisher’s exact
tests, as appropriate. All p values were reported as two-
sided, and values <0.05 were considered statistically signifi-
cant. This study was approved by the Institutional Review
Board of the Shizuoka Cancer Center (22-34-22-1-7).
Results
Patient characteristics
A total of 129 patients were diagnosed with squamous
cell lung cancer or adenosquamous carcinoma and were
included in this study from July 2011 to November
2012. The characteristics of the patients are shown inA
B
Figure 2 Relative proportions of genetic alterations in surgically rese
embedded samples (C and D, n = 65) from patients with squamous ce
relative proportions of genetic alterations in surgically resected snap-frozen
in surgically resected snap-frozen samples. C: Bar chart shows relative prop
chart shows relative proportions of genetic alterations in paraffin-embeddeTable 2. The median age was 70 years (range: 38–92),
and most patients were male and smokers. Histologically,
adenosquamous carcinoma was observed in six (5%) of
the patients. Well-differentiated, moderately-differentiated
and poorly-differentiated squamous cell carcinomas were
present in 10%, 53% and 27% of the patients, respectively.
Stage I, II, III and IV were observed in 26%, 29%, 26% and
19%, respectively. Surgically-resected, snap-frozen samples
were obtained from 64 patients (50%), and FFPE samples
from 65 patients (50%).
Genetic alteration profiles
We detected genetic alterations in 40% of all cases. Figure 1
shows the frequencies of genetic alterations in patients
with squamous cell lung cancer. The genetic alterations
included: EGFR mutation in eight (6%); KRAS mutation in
five (4%); PIK3CA mutation in 17 (13%); NRAS mutation
in one (1%); KIF5b-RET fusion in one (1%); EGFR copy
number gain in six (5%); PIK3CA copy number gain in
19 (15%); and FGFR1 copy number gain in six (5%)
(Additional file 3: Table S2 and Additional file 4: TableC
D
cted snap-frozen samples (A and B, n = 64) and paraffin-
ll lung cancer and adenosquamous carcinoma. A: Bar chart shows
samples. B: Pie chart shows relative proportions of genetic alterations
ortions of genetic alterations in paraffin-embedded samples. D: Pie
d samples. MUT: mutant, CNG: copy number gain.
Kenmotsu et al. BMC Cancer 2014, 14:786 Page 5 of 7
http://www.biomedcentral.com/1471-2407/14/786S3). Of eight patients with EGFR mutation, four had
the L858R point mutation in exon 21, and three had
deletions in exon 19. In addition, the frequencies of
genetic alterations in surgically-resected, snap-frozen
samples and FFPE samples from patients with squa-
mous cell lung cancer were analyzed (Figure 2), and
the following alterations were detected: EGFR muta-
tion in 8% and 5%, KRAS mutation in 3% and 5%,
PIK3CA mutation in 17% and 9%, EGFR copy number
gain in 8% and 2%, PIK3CA copy number gain in 19%
and 11%, and FGFR1 copy number gain in 8% and 2%,
respectively.
Clinicopathological factors related to genetic alterations
The results of univariate analysis of clinicopathological
factors for genetic alterations are shown in Table 3. Genetic
alterations were significantly more frequent in surgically-Table 3 Frequency of genomic alterations in
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FFPE formalin-fixed paraffin-embedded.resected, snap-frozen samples than in FFPE samples (50%
vs. 29%, p = 0.015). In addition, patients ≤70 years old and
“never-smokers” showed higher frequencies of genetic al-
terations. Also, 75% of patients ≤60 years old (n = 12) had
genetic alterations including EGFR mutation in 2, KRAS
mutation in 2, PIK3CA mutation in 2, KIF5b-RET fu-
sion in 1, EGFR copy number gain in 2, and PIK3CA
copy number gain in 2.Discussion
This study represents one of the largest, prospective,
tumor-genotyping studies carried out in Asian patients
with squamous cell carcinoma of the lung. Genetic alter-
ations were detected in 40% of patients in this study.
There have been few reports on the gene alterations
associated with squamous cell lung cancer. However, the
Cancer Genome Atlas Research Network performed a
comprehensive genomic analysis of 178 squamous cell lung
cancers and reported the following genetic alterations:
PIK3CA mutations in 16%, PTEN mutation/deletion in
15%, FGFR1 amplification in 15%, EGFR amplification in
9%, PDGFRA amplification in 9%, DDR2 mutation in 4%,
and unknown genetic alterations in 21% [8]. In addition,
multiplex testing for driver mutations in 72 squamous cell
carcinomas of the lung detected: PIK3CA mutations in 8%,
PTEN mutation/deletion in 28%, FGFR1 amplification in
26%, and unknown genetic alterations in 39% [9]. Korean
study showed a similar spectrum of gene alterations
between East Asian and North American [10]. Genetic
alterations in patients enrolled in the current prospect-
ive study may reflect the frequencies of genetic alter-
ations in the clinical setting, and suggest that genetic
profiling in Japanese patients may be similar to that in
North American.
Genetic alterations were seen more frequently in
surgically-resected, snap-frozen samples, in patients ≤70 years
old, and in “never-smokers”. FFPE specimens are subject to
increasing DNA degradation as they get older [17], which
may account for the difference in frequencies of genetic
alterations between snap-frozen and FFPE samples. Squa-
mous cell lung cancer is strongly associated with cigarette
smoking [18] and 98% of patients with squamous cell car-
cinoma in this study were light or heavy smokers. Although
all three “never-smokers” showed genetic alterations (EGFR
mutation, EGFR or PIK3CA copy number gain), the sample
size was too small to evaluate these results. The association
between age and genetic alterations is unclear. Multiple
genetic alterations were reported to be more common in
younger patients with papillary thyroid cancer [19], while
younger patients with colorectal cancer showed a high
frequency of KRAS mutations [20]. In contrast however, a
positive association between EGFR mutation and age was
reported among never-smoker lung cancer patients [21].
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http://www.biomedcentral.com/1471-2407/14/786In this study, PIK3CA mutation was relatively fre-
quent in squamous cell lung cancer, as reported in
other studies, while FGFR1 copy number gain seemed
less frequent [8,9]. The phosphoinositide 3-kinase
(PI3K) pathway is a key oncogenic signaling pathway
that functions in cell survival and proliferation [22].
The PIK3CA gene encodes the PI3K catalytic subunit
α-isoform and is frequently mutated in some of the
most common human tumors. Our earlier study, as
well as other studies, found that PIK3CA mutations
were more common in squamous cell lung cancer
than in lung adenocarcinoma [23-25]. The fibroblast
growth factor receptor (FGFR) is a transmembrane
receptor tyrosine kinase that participates in the
regulation of embryonal development, cell prolifera-
tion, differentiation, and angiogenesis [26,27]. The
frequency of FGFR1 amplification in surgical speci-
mens has been reported to be 13–41%, and does not
seem to differ according to ethnicity [28-30]. However,
the frequency of FGFR1 copy number gain in this
study was only 4% of all samples and 8% of fresh-
frozen samples. This apparent discrepancy in the fre-
quencies of FGFR1 copy number gain may be a result
of the different methodologies used in the studies,
and/or the influence of biopsy samples from patients
with metastatic squamous cell lung cancer. PIK3CA
mutation and FGFR1 amplification both represent
potential targets for personalized squamous cell lung
cancer therapy, and it may therefore be important
to analyze both these gene alterations in clinical
practice.
A major limitation of this study was that genetic alter-
ations were analyzed using a genotyping panel, rather
than by a comprehensive analysis. However, the object-
ive of this study was not only to assess the frequencies
of driver gene mutations, but also to assign patients to
appropriate therapies and/or enrollment in clinical trials.
Our genotyping panel included most gene mutations
that are targeted by new drugs in ongoing clinical trials.
This study was also limited by intratumor heterogeneity,
which may have resulted in underestimation of tumor
genetic alterations [31]. It is difficult to obtain multiple
lesions by tumor biopsy in the clinical setting, but we in-
tend to address this challenge in the future to aid further
progress in biomarker development.
Conclusion
Genetic alterations were detected in 40% of Japanese
patients with squamous cell lung cancer. These results
suggest that incorporation of genetic profiling into lung
cancer clinical practice may facilitate the administration
of personalized cancer treatments in patients with squa-
mous cell lung cancer, though further studies are needed
to verify these results.Additional files
Additional file 1: Table S1. Tumor genotyping panel developed for
this study.
Additional file 2: Supplementary methods.
Additional file 3: Table S2. Distribution of genetic alterations in each
gene.
Additional file 4: Table S3. Distribution of concurrent genetic alterations.
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